Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

THG indictment

This article was originally published in The Tan Sheet

Executive Summary

San Francisco grand jury returns 42-count indictment against four defendants associated with distributing anabolic steroids including tetrahydragestrinone (THG), Justice Department announces Feb. 12. Case was brought by FDA Commissioner Mark McClellan, MD/PhD, Attorney General John Ashcroft, IRS Commissioner Mark Everson and U.S. Attorney Kevin Ryan. Charges include conspiracy to possess with intent to distribute anabolic steroids, violating the FD&C Act by misbranding THG and failing to correctly label the drug being sold. The indictment also alleges six separate occasions in which steroids actually were distributed to athletes. The four defendants are Bay Area Lab Cooperative President Victor Conte and VP James Valente, personal trainer Greg Anderson and track coach Remi Korchemny. THG previously was marketed as a dietary supplement, but was banned by FDA in October (1"The Tan Sheet" Nov. 3, 2003, p. 14)...

You may also be interested in...



THG Controversy Spotlights Growing Sports Supplement Concerns

FDA's ban of tetrahydrogestrinone (THG) represents another black eye for sports supplements, coinciding with the highly publicized debate over the safety of ephedra-containing products

IIL-Griffith Univ Readying Reasonably Priced COVID-19 Vaccine

The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.

Cipla Granted Approval For First US Proventil Rival

Shortly after wrapping up a Phase III trial for its proposed generic Advair Diskus product in the US, Cipla has won FDA approval for the first generic Proventil HFA product, as it continues to build up steam in the US respiratory market.

Topics

UsernamePublicRestriction

Register

PS096488

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel